Pfizer submits clinical data to FDA for vaccine booster shot approval
Category: #health  By Mateen Dalal  Date: 2021-08-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pfizer submits clinical data to FDA for vaccine booster shot approval

Leading vaccine developers, Pfizer and BioNTech have recently submitted primary stage clinical data to the U.S. FDA (Food and Drug Administration) as a part of their efforts to authorize booster vaccine shot for COVID-19 for everyone aged above 16, including ones with weak immune system.

In a press release, the companies said that volunteers in the clinical trial received a third dosage of the two-dose vaccine roughly eight to nine months following their second shot. In the trial, the vaccine booster dose generated higher neutralizing antibodies against the original coronavirus strain and the beta and delta variants.

Pfizer CEO, Albert Bourla says that the data they have seen suggests that third dose of vaccines produces higher antibodies than those produced after both doses. As a result, they are thrilled to submit this application to the FDA as they continue to collaborate to meet the pandemic's growing challenges.

According to the firm, late-stage research results evaluating the third dose are anticipated soon and will be submitted to the FDA and other regulatory agencies worldwide.

The drug makers announcement comes after the federal health officials approved using Covid booster shots on Americans with weak immune system, which comprises HIV and cancer patients and people who have undergone organ transplants.

The new data from the U.S. suggests that immune-compromised individuals do not produce enough immune response after getting jabbed with two doses of the Covid vaccine.

Although, Federal health officials still don’t recommend the booster dose for the general public, White House chief medical advisor, Dr. Anthony Fauci has indicated that every individual would require a booster shot at some point.

Similarly, Covid vaccine makers, including Pfizer and Moderna, have said that every individual will need a booster shot and possibly extra doses each year like seasonal flu.

Source Credit - https://www.cnbc.com/2021/08/16/covid-vaccine-booster-shot-pfizer-submits-data-to-fda-for-approval.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

G42 Healthcare & AstraZeneca ink LOI to innovate in Life Science
G42 Healthcare & AstraZeneca ink LOI to innovate in Life Science
By Mateen Dalal

G42 Healthcare, an AI-powered healthcare company, has reportedly inked an LOI (Letter of Intent) with AstraZeneca, a global science-led biopharmaceutical company, with an intention to enlarge their collaboration into the diagnostics and clinical rese...

Tata Steel Purchases coal from Russia after pledging to cut business ties
Tata Steel Purchases coal from Russia after pledging to cut business ties
By Mateen Dalal

In April, Tata Steel, India’s top steel maker, had announced that all its manufacturing units in the UK, India, and Netherlands had sourced substitute raw materials supplies to end its dependency on Russia. The company further stated that the d...

Coforge, Estes Express Lines to offer next-gen solutions to T&L sector
Coforge, Estes Express Lines to offer next-gen solutions to T&L sector
By Mateen Dalal

Coforge, an Indian multinational information technology company, is reportedly planning to collaborate with Estes Express Lines, a privately owned American freight transportation provider to offer agile, next-generation solutions to the transportatio...